FY26 Full Year Results & Investor Webinar
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The company achieved a notable increase in revenue and positive operating cash flow across all quarters of the year. Highlights include a substantial rise in earnings and a reduction in employee costs as a percentage of revenue, reflecting improved operational efficiency. The CEO expressed confidence in the company's strategy and provided guidance for the upcoming fiscal year, anticipating further revenue growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Resonance Health
- Liver Fibrosis Device Progress & FY26 Portfolio Webinar
- Profit Guidance Upgrade
- Receipt of R&D Tax Incentive Refund
- Half Year Results Presentation
- Half Year Results
Later from Resonance Health
- Global Strategic Alliance & MSA with Image Analysis Group
- Trading Halt
- Liver Fibrosis Device - EPoC Study Results
- $6.0 Million Placement Oversubscribed
- Investor Presentation Liver Fibrosis Device & Capital Raise
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health